Drug delivery technologies development

The aim of this review is to consider the types of medications/drug delivery systems that could be developed for administration in battlefield situations, current systems and possible future developments. It will consider battlefield situations, the medical aid provided, current drug delivery technologies and those employed at the front line, followed by a consideration of some future possible developments. 

Rong (Ron) Liu has been in the pharmaceutical industry for 20 years, and is currently leading AustarPharma, a pharmaceutical company based at Edison, New Jersey. The core competence of the company is drug delivery technologies. Before his current role, Ron was employed at Bristol-Myers Squibb (BMS) as a director of global product development for more than 5 years. 

Maggio, E.T. 2005. Recent developments in intranasal drug delivery technology are creating new vistas for peptide and protein therapeutics. Drug Deliv Comp Report, Spring/Summer 34 37. 

D. Bar-Shalom, L. Slot, W. W. Lee, and C. G. Wilson. Development of the Egalet technology, in Michael J. Rathbone, Jonathan Hadgraft, and Machael S. Roberts (eds.), Drugs and the Pharmaceutical Sciences, Vol. 126 Modified-Release Drug Delivery Technology. New York Marcel Dekker, 2003, pp. 263-271. 

Evers, P. (1997) Developments in drug delivery technology markets, 2nd edn. Financial Times Pharmaceutical and Healthcare Publishing. 

Evers, P. Developments in Drug Delivery Technology Markets Healthcare and Pharmaceutical Publishing London, 1995 Financial Times. 

Considerable advances have taken place in pharmaceutical industry during the past two decades. Contemporary trends in pharmaceutical product development that are relevant to DDS are listed in Table 1.10. Drug delivery technologies have become an important part of the biopharmaceutical industry. Drug delivery systems, pharmaceutical industry, and biotechnology interact with each other as shown in Fig. 1.1. 

Drug delivery technologies are aimed at improving efficacy and safety of medicines as well as commercial pharmaceutical development. The following are the important points ... 

However, subjective and objective analyses of these devices are required to make sure both scientific, regulatory and consumer needs are met. The devices in development are costlier and more complicated when compared with conventional transdermal patch therapies. As such they may contain electrical and mechanical components which could increase the potential safety risks to patients because of poor operator technique or device malfunction. In addition, effects of the device on the skin must be reversible, since any permanent damage to the SC will result in the loss of its barrier properties and hence its function as a protective organ. Regulatory bodies will also require data to substantiate the safety of the device on the skin for either short- or long-term use. Thus, for any of these novel drug delivery technologies to succeed and compete with those already on the market, their safety, efficacy, portability, user-friendliness, cost-effectiveness and potential market have to be addressed. 

The device structure is a modification of that presented by Chung et al. [13], and based on the fusion of previous active implantable drug delivery technologies [14] with our recently developed electrokinetically active... 

As in all chemistry, the ultimate goal of supramolecular chemistry is to relate structure to function. Electronic spectroscopy can be valuable on both sides of the game when it comes to the study of CyD inclusion complexes. On one hand, it is of virtually general use in monitoring the formation of complexes by their influence on measured spectra, and is on a par with other techniques in the quantitative study of association equilibria [2-4] this is widely used in pharmaceutical chemistry in the development of drug-delivery technology [5]. On the other hand,... 

---